Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ralf-Axel Hilger"'
Autor:
Margarita Melnikova, Ulrike Sophie Wauer, Diana Mendus, Ralf Axel Hilger, Trudy G. Oliver, Kim Mercer, Björn Oliver Gohlke, Kati Erdmann, Dieter Niederacher, Hans Neubauer, Paul Buderath, Pauline Wimberger, Jan Dominik Kuhlmann, Jürgen Thomale
Publikováno v:
Molecular Oncology, Vol 14, Iss 4, Pp 686-703 (2020)
Platinum‐based compounds remain a well‐established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type‐specific toxicity and the clinical responsi
Externí odkaz:
https://doaj.org/article/c92a25a31abc4582925f02044ae84d0e
Autor:
Weber, Elisabeth Groß, Ralf-Axel Hilger, Franziska Lea Schümann, Marcus Bauer, Alyssa Bouska, Christian Rohde, Edith Willscher, Jana Lützkendorf, Lutz Peter Müller, Bayram Edemir, Thomas Mueller, Marco Herling, Mascha Binder, Claudia Wickenhauser, Javeed Iqbal, Guido Posern, Thomas
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 3043
T-cell lymphomas are heterogeneous and rare lymphatic malignancies with unfavorable prognosis. Consequently, new therapeutic strategies are needed. The enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::17ff832a2aff13e82b3ac4a8b44cb185
Autor:
Jens T. Siveke, Diana Behrens, Stephan A. Hahn, Ralf Axel Hilger, Samuel Peña-Llopis, Konstantinos Savvatakis, Jiang-Ning Gu, Silvia Vega-Rubin-de-Celis, Ben Zhao, Smiths S Lueong, Laura Dierichs, Sven-Thorsten Liffers, Marija Trajkovic-Arsic
Publikováno v:
Cell Death Discovery, Vol 6, Iss 1, Pp 1-13 (2020)
Cell Death Discovery
Cell Death Discovery
Oncogenic KRAS mutations are encountered in more than 90% of pancreatic ductal adenocarcinomas. MEK inhibition has failed to procure any clinical benefits in mutant RAS-driven cancers including pancreatic ductal adenocarcinoma (PDAC). To identify pot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1a110291840440fed468708b9b8973b
https://doi.org/10.1038/s41420-020-0246-7
https://doi.org/10.1038/s41420-020-0246-7
Autor:
F. Bach, Norbert Marschner, Dirk Reuter, Dirk Strumberg, Ralf Axel Hilger, Max E. Scheulen, F. Lordick, Beate Schultheis, Jürgen Krauss, K. Mross, Lutz Edler
Introduction Nimotuzumab is a humanized monoclonal antibody that binds to the EGFR. Based on phase I data, the recommended dose has been established at 200 mg weekly. This study was aimed at evaluating the safety and efficacy of nimotuzumab monothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b624997d237bf42a8e8f59fa6c382749
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84864375346
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84864375346
